Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P010031/S934

Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D

Medtronic Cardiac Rhythm Disease Management · Decision date Oct 29, 2026

MEDTECHLEDGER EXPLANATIONP010031/S934

What did the FDA decide?

The FDA record for P010031/S934 covers a 30-Day Notice from Medtronic Cardiac Rhythm Disease Management concerning the Cobalt MRI CRT-D, Cobalt XT MRI CRT-D and Crome MRI CRT-D devices, classified under product code NIK as automatic implantable cardioverter defibrillators with cardiac resynchronization. The supplement reason is logged as a process change involving manufacturer, sterilizer, packager or supplier. Its stated purpose is to adjust the rise time measurement upper limit during final functional electrical testing.

S934 is a supplement to PMA P010031, so the identifier ties it to that original application rather than establishing a separate approval of the whole system. The notice describes a testing-limit adjustment, not a clinical study result, and no details are provided on the prior limit, the new limit, or the rationale. The entry therefore does not demonstrate safety or effectiveness on its own.

FDA approval order statement

to adjust rise time measurement upper limit during final functional electrical testing
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P010031/S934
Regulatory pathway
PMA supplement
Product code
NIK
Decision code
OK30
Decision date
Oct 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D).

Product code
NIK
FDA device class
3

For the original device and its historical approval scope, see PMA P010031. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P010031 · Original PMA

    CONCERTO/INSYNC SENTRY/INSYNC MAXIMO IMPLANTABLE CARDIOVASCULAR DEFIBRILLATORS WITH CARDIAC RESYNCHICNIZATION

  2. P010031/S932 · Related supplement

    Cobalt MRI CRT-D, Cobalt XT MRI CRT-D, Crome MRI CRT-D

  3. P010031/S934 received

    Application receipt date recorded by FDA.

  4. P010031/S933 · Related supplement

    Cobalt MRI CRT-D (DTPB2Dl, DTPB2D4, DTPB2Ql, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2Dl, DTPA2D4, DTPA2Ql, DTPA2QQ); Crome M

  5. P010031/S934 · FDA decision

    30-Day Notice

  6. P010031/S931 · Related supplement

    Cobalt MRI CRT-D (DTPB2D1, DTPB2D4, DTPB2Q1, DTPB2QQ); Cobalt XT MRI CRT-D (DTPA2D1, DTPA2D4, DTPA2Q1, DTPA2QQ); Crome M

Timeline entries are records held by MedtechLedger for P010031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P010031

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic Cardiac Rhythm Disease Management

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records